L. Zheng

Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations.

P. Jänne, Ying Cheng, C. Chiu, 2021 .

Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors

Yang Xu, Q. Ou, Gefei Zhao, 2023, Neoplasia.

New insights into the genetics of primary open-angle glaucoma based on meta-analyses of intraocular pressure and optic disc characteristics

Adriana I. Iglesias, A. Hofman, A. Uitterlinden, 2017, Human molecular genetics.

Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.

Ying Cheng, C. Chiu, P. Janne, 2022, Journal of Clinical Oncology.

Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Ying Cheng, C. Chiu, P. Janne, 2022, Cancer discovery.

Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results.

Ying Cheng, Yanqiu Zhao, Yong He, 2023, Journal of Clinical Oncology.